MUN/GX1 (MUN/GX1)

Munich Stock Exchange: MUN/GX1 · EUR

€0.85

+0.01 (+0.6%)· Recorded snapshot

Market cap	14.3M
Revenue (ttm)	3.1M
Net income (ttm)	-7.6M
EPS (ttm)	-€0.42
Volume	0

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.1M
Net income (ttm): -7.6M
EPS (ttm): -€0.42
Market cap: 14.3M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-76.9

P25 n/aP50 n/aP75 n/a

ROIC-52.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MUN/GX1 indicators

Market & fundamental data

Available fields

147

Groups with data

Currency

USD

Showing 147 of 147 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	United States
Country code	DE
Earnings date	2026-11-13
Employees	5
Employees change	0
Employees growth	0%
Enterprise value	EUR 4.2M
Exchange	Munich Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-10-27
Fiscal year end	December
Founded	1999
Industry	Biotechnology
Is primary listing	No
ISIN number	US57055L2060
Last refreshed	2026-10-28
Last stock split date	2023-01-27
Last stock split type	Reverse
Market cap	EUR 14.3M
Next earnings date	2026-11-13
Price	EUR 0.85
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	mun/GX1
Website	https://markertherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-49.54%
EV/Sales	1.28x
FCF / EV yield	-215.52%
FCF yield	-61.55%
P/B ratio	1.34x
P/S ratio	4.59x
Price / tangible book value	1.34x
Sector forward P/E	14.8x
Sector P/E	39.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-267.95%
Gross margin	-148.28%
Operating margin	-267.95%
Pretax margin	-245.94%
Profit margin	-245.51%
Profit per employee	EUR -1.5M
Revenue per employee	EUR 620,880
ROA	-40.47%
ROA (5Y)	-35.24%
ROCE	-78.12%
ROE	-76.87%
ROE (5Y)	-79.54%
ROIC	-52.43%
SBC / revenue	14.62%
Tax / revenue	-0.43%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	1
Net income growth quarters	4
Net income growth years	0
Revenue growth	-15.11%
Revenue growth 3Y	-1.89%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	EUR -8.3M
EPS	EUR -0.42
Financing cash flow	EUR 8.6M
Free cash flow	EUR -8.8M
Free cash flow minus SBC	EUR -9.2M
Gross profit	EUR -4.6M
Income taxes	EUR -13,266
Net cash flow	EUR 93,995
Net income	EUR -7.6M
Operating cash flow minus SBC	EUR -9.2M
Operating income	EUR -8.3M
Revenue	EUR 3.1M
Stock-based compensation	EUR 453,902

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-40.36
Book value per share	EUR 0.64
Debt / equity	0
Long-term assets	EUR -332,943
Long-term liabilities	EUR -55,242
Net cash (debt)	EUR 9.9M
Net cash / market cap	69.67%
Net cash growth	8.31%
Net debt / equity	-0.93
Piotroski F-Score	2
Shareholders' equity	EUR 10.6M
Tangible book value	EUR 10.6M
Tangible book value per share	EUR 0.64
Total assets	EUR 12.8M
Total cash	EUR 9.9M
Total debt	EUR 0
Total liabilities	EUR 2.1M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.24
Current assets	EUR 13.1M
Current liabilities	EUR 2.2M
Current ratio	6.03
Net working capital	EUR 730,386
Quick ratio	5.35
Working capital	EUR 10.6M
Working capital turnover	0.27

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-73.22%
Shareholder yield	-73.22%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	0.6%
1M price change	-36.84%
1M total return	-36.84%
1Y price change	14.29%
1Y return CAGR	14.3%
1Y total return	14.29%
20-day SMA	EUR 1.03
3M price change	-36.84%
3M total return	-36.84%
52-week high	EUR 1.81
52-week high date	2026-01-23
52-week low	EUR 0.81
52-week low date	2025-11-11
6M price change	-35.88%
6M total return	-35.88%
All-time high	EUR 5.20
All-time high date	2024-12-17
All-time low	EUR 0.72
All-time low date	2025-09-03
Average true range (ATR)	EUR 0.30
Average volume	1.5K
Change from 52-week high	-53.31%
Change from 52-week low	4.32%
Change from all-time high	-83.85%
Change from all-time low	17.48%
Change from open	0%
Day's gap	0.6%
High price	EUR 0.85
Low price	EUR 0.85
Monthly RSI	40.33
Open price	EUR 0.85
Previous close	EUR 0.84
Price vs 20-day SMA	-18.53%
Relative volume	2.28
RSI	40.16
Sharpe ratio	-0.19
Sortino ratio	-0.32
Volume	0
Weekly RSI	0
YTD price change	-1.75%
YTD total return	-1.75%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	13.7M
Shares change (QoQ)	0%
Shares change (YoY)	73.22%
Shares held by insiders	7.82%
Shares held by institutions	16.08%
Short ratio	1 days

Deeper analysis on MUN/GX1

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MUN/GX1 report

Is a complete MUN/GX1 research report available?

No complete published report is available for mun/GX1 (MUN/GX1) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

MUN/GX1 (MUN/GX1)

Price

Financial snapshot

Fair-value bridge

Latest news · MUN/GX1

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All MUN/GX1 indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MUN/GX1

Frequently asked questions